Frailty and Type 2 Diabetes Guidelines for clinicians
|
|
- Jocelin Barnett
- 5 years ago
- Views:
Transcription
1 H.G. WELLS PROJECT Frailty and Type 2 Diabetes Guidelines for clinicians Victoria Ruszala victoria.ruszala@nhs.net H.G. Wells Project team Dugal T, Partington E. Kernow CCG Diabetes and Frailty Guideline 1 October 2015 Review date: October 2017
2 1. Introduction This guideline endorses a wider range of acceptable HbA1c targets in older patients. Treatment decisions can be based on the level of frailty and tolerability of hyperglycaemia and individualized treatment decisions can be made. Although acceptance of high HbA1c levels near 108 mmol/mol may be the exception, it is unnecessary to alter therapy if an individual has tolerated high HbA1c levels for many years, has limited life expectancy, and has no hyperglycaemia-associated symptoms. All patients with diabetes (including type 1 diabetes) who are older than 70 years should be assessed using a validated frailty scale. Younger individuals should also be assessed if clinically appropriate. The recommended scale is the Rockwood scale detailed in Appendix One. The following recommendations for treatment are based upon the use of the scale to assess the individual and their level of frailty. It should be remembered that patient conditions can vary and therefore a single time point assessment may need to be reviewed at a later date. 2. Treatment aims Treatment aims should be decided on an individual basis. The following guidance from ADA/EASD (American Diabetes Association and European Association for the Study of Diabetes) provides a treatment scale to determine patient and disease factors that may be used to determine optimal HbA1c targets. The ranges provided in Table 1 are idealised and therefore exceptions can be made where clinical necessity dictates. Where possible, such decisions should be made with the patient, reflecting his or her preferences, needs, and values. This scale is not designed to be applied rigidly but to be used as a broad construct to guide clinical decision making. 1
3 3. Approach to the management of hypoglycaemia NB. This algorithm is taken from Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Inzucchi et al. (2012) The IFCC units are not used in the US or across all of Europe therefore the aim of 7% is listed. This can be interpreted as 53mmol/mol for the purpose of UK practice. 2
4 Table 1. Treatment Aims The key aim of treatment in frail patients is avoidance of hypoglycaemia and hyperglycaemia which can increase hospital admissions, aggravate co-morbidities and reduce quality of life. Hypoglycaemia: Capillary blood glucose levels less than 4.0mmol/L (or HbA1c <50mmol/mol) can exacerbate dementia and confusion, increase likelihood of falls and cardiac arrhythmias Hyperglycaemia: Levels above 15.0mmol/L (or HbA1c >80mmol/mol) put patients at risk of dehydration, electrolyte abnormalities, urinary incontinence, dizziness and falls. Older patients with multiple co-morbidities are also at much higher risk of adverse drug reactions (ADRs) and these should be considered with every treatment review. Level of Frailty Rationale Therapeutic targets Blood Pressure and Lipids 1 Elderly (over 70 years) with life expectancy likely to be over 10 years None or mild complications Few co-existing chronic illnesses, intact cognitive and functional status Rockwood - Up to Mildly Frail Longer remaining life expectancy Prevention of deterioration of complications and comorbidities HbA1c: 53 to 58 mmol/mol (7%- 7.5%) Fasting or pre-prandial CBG: mmol/l Bedtime CBG: mmol/L NB: CBG in this range will help to achieve HbA1c. However occasional deviations are not problematic. BP <140/80 if tolerated (avoid falls) Statin unless contraindicated or not tolerated In patients over the age of 70 controlling BP and lipids has a far greater beneficial effect than reducing HbA1c 2 Elderly (over 70 years) and life expectancy likely to be less than 10 years Multiple complications Multiple co-existing chronic illnesses or 2+ Activities of Daily Living (ADL) impairments or mild to moderate cognitive impairment Rockwood - Moderately Frail Intermediate remaining life expectancy High treatment burden Hypoglycaemia vulnerability Falls risk HbA1c: 60 to 69mmol/mol (7.6%- 8.5%) Fasting or pre-prandial CBG: mmol/l Bedtime CBG: mmol/L NB: CBG in this range will help to achieve HbA1c. However occasional deviations are not problematic. BP <140/80 if tolerated Statin unless contraindicated or not tolerated. In patients over the age of 70 controlling BP and lipids has a far greater beneficial effect than reducing HbA1c 3
5 Level of Frailty Rationale Therapeutic targets Blood Pressure and Lipids 3 Elderly (over 70 years) and life expectancy likely to be much less than 10 years Multiple or end-stage co-morbidities Long term care facility 2+ ADL dependencies or moderate to severe cognitive impairment Limited life expectancy makes benefits uncertain HbA1c: 60 to 75mmol/mol (7.6%- 9%). Higher levels are acceptable as long as patients have no hyperglycaemic symptoms and have tolerated these levels for a long period of time and do not have risk factors for HHS. BP <150/90 if tolerated Consider likelihood of benefit with statin (secondary prevention more likely to benefit than primary prevention) Rockwood Severely Frail or Very severely Frail Fasting or pre-prandial CBG: mmol/L Bedtime CBG: mmol/L Includes: Moderately frail patients requiring paramedic for hypo management or admitted to hospital with hyper- or hypo glycaemia. NB: CBG in this range will help to achieve HbA1c. However occasional deviations are not problematic. NB. CBG: Capillary Blood Glucose 4
6 Table 2. Treatment choices Frailty level Suggested actions and therapeutic options. NICE guidance and BNSSG formulary should be followed where possible to determine first line choices 1. Metformin remains first line treatment. 2. Avoid starting sulphonylureas in elderly. Review existing sulphonylurea use. 3. Appropriate to use DPP4 inhibitors for second line therapy. Consider SGLT-2 inhibitors if renal function is sufficient. 4. Pioglitazone should be avoided due to risk of heart failure. 5. Weight loss associated with GLP-1 agonists should be monitored carefully. 6. First choice of insulin remains NPH insulin. 7. Combination of all of these agents with insulin is appropriate to minimise insulin doses required. 8. Ensure appropriate CV risk reduction medication is maintained. 9. Reassess/Reduce if worsening frailty or hypoglycaemia occurs. 1. Main treatment aim is hypoglycaemia avoidance and hyperglycaemic symptoms. 2. Assess renal function regularly. Caution with metformin (and other drugs) if egfr ml/min/1.73m 2. Reduce or stop drugs as necessary. (egfr is known to over-estimate renal function in frail elderly patients and creatinine clearance should be calculated using the Cockroft Gault equation) 3. Consider insulin treatment to control hyperglycaemia with symptoms. NPH insulin remains first line. Analogue insulin should be considered where hypoglycaemia has occurred or if patient requires assistance with administration. Combination with other products to minimise doses required and/or weight gain is appropriate. 4. Do not restrict diet if low or losing weight. GLP-1 agonist use should be reviewed regularly. 5. Review blood pressure regularly. Minimise number of agents used and decrease targets if patient is at risk of falls or lives alone. ACE inhibitors remain first line choice although will need review in worsening renal impairment. 6. Reassess/Reduce if worsening frailty or hypoglycaemia occurs. 1. De-escalate treatment Reduce drug doses and treatments. 2. Consider whether oral or injectable diabetes therapies can be stopped. 3. Consider whether possible to stop insulin (seek advice) or minimise doses given. 4. Stop metformin (and caution with other drugs) if egfr is deteriorating, consistently below 30 ml/min/1.73m 2, or acute kidney injury has occurred recently. 5. Stop lipid lowering drugs. 6. Review and possibly stop diuretics (increases risks of falls, dehydration and HHS). 7. Stop /reduce other drugs likely to cause adverse effects. 5
7 References 1. Sinclair AJ et al on behalf of European Diabetes Working Party for Older People. Clinical Guidelines for Type 2 Diabetes Mellitus. Diabetes Metab, 2011; 37(Suppl 3):S Kirkman MS, Briscoe VJ, Clark N et al. Consensus Report: Diabetes in Older Adults. Diabetes Care, 2012; 35: Meneilly GS, Knip A, Tessier D on behalf of the Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Clinical Practice Guidelines: Diabetes in the Elderly. Can J Diabetes, 2013; 37:S184-S Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015; 38(1): This paper has been reviewed and commented on by the following: North Bristol Trust Diabetes Team Jarrod Richards (Consultant, NBT Complex Adult Liason Service) UHBristol Diabetes Team Simon Croxon (Consultant, elderly care and diabetes specialist) Bristol CCG Meds Optimisation Team Bristol Community Health Diabetes Specialist Nurses H.G. Wells Project Team The paper was also sent to the Weston Diabetes Team. 6
8 Appendix One: Rockwood Frailty Scale Figure 1.Clinical frailty scale.adapted with permission from Moorhouse P, Rockwood K. Frailty and its quantitative clinical evaluation.j R Coll Physicians Edinb. 2012;42:
Managing Type 2 Diabetes in Frailty within Primary Care
Managing Type 2 Diabetes in Frailty within Primary Care Author Medicines Management Pharmacist Version 1.0 Written: May 2017 Next review: May 2018 Approved by IESCCG Workstream Date approved 27/6/17 Contents
More informationDiabetes Mellitus in Older Adults. Presenter Disclosure Information
Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from
More informationGuideline for antihyperglycaemic therapy in adults with type 2 diabetes
Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Version Control Version Number Date Amendments made 1 January 2018 1.1 February 2018 Amended to reflect updated SPC advice for sitagliptin
More informationDiabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust
Diabetes Update: Keeping patients safe Victoria Ruszala MFRPSII North Bristol NHS Trust Declaration of Interests I have received funding from the following companies for providing education sessions, attending
More informationDiabetes Management in New Brunswick Nursing Homes
Diabetes Management in New Brunswick Nursing Homes Prepared by Dr. Angela McGibbon March, 2016 As the population ages and with the rising incidence of diabetes, there are increasing numbers of people with
More informationDiabetes is very common in older people, Glycaemic control in the elderly: What should we be aiming for? Article. Andrew McGovern
Article Glycaemic control in the elderly: What should we be aiming for? Andrew McGovern Diabetes is very common in older people, who are at high risk of diabetes-related complications. Overtreatment in
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes
National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationPeri-operative management of the surgical patient with diabetes GL059
DT Peri-operative management of the surgical patient with diabetes GL059 Approval Approval Group Job Title, Chair of Committee Date Anaesthetics Clinical Governance Chair Anaesthetic governance Nov 2016
More informationOlder Adults & Optimal Outcome. Individualizing Diabetes Management. Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC
Older Adults & Optimal Outcome Individualizing Diabetes Management Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC What is Diabetes? METABOLIC DISEASE Food breakdown (carbohydrates,
More information667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY
667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY Contents Introduction... 1 Patient Education for People with Type 2 Diabetes... 2 Dietary Advice for People with Type 2 Diabetes...
More information9 Diabetes care. Back to contents
Back to contents Diabetes is a major risk factor for the development of peripheral vascular disease and 349/628 (55.6%) of the patients in this study had diabetes. Hospital inpatients with diabetes are
More informationManaging Hyperglycaemia in Acute (Adult) Inpatients Requiring Enteral Feeding Guidelines
Document Control Title Managing Hyperglycaemia in Acute (Adult) Inpatients Requiring Author Author s job title Specialist Nurse Consultant Physician Department Directorate Unscheduled Care Version Date
More informationDr A Pokrajac MD MSc MRCP Consultant
Dr A Pokrajac MD MSc MRCP Consultant Onset at 5-15 years of T1DM Can be present at diagnosis of T2DM Detect in regular MA/Cr screening (2X first urine sample, no UTI, no other causes) Contributing Factors
More informationTeam-Based Approaches to Help Older Adults With Type 2 Diabetes Achieve Individualized Glycemic Goals
Team-Based Approaches to Help Older Adults With Type 2 Diabetes Achieve Individualized Glycemic Goals 1. Which one of the agents listed here is widely considered the first-line therapy in type 2 diabetes
More informationDr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?
Dr Tahseen A. Chowdhury Royal London Hospital New Guidelines in Diabetes: NICE or Nasty? I have no conflicts of interest I do not undertake talks / advisory bodies / research for any pharma company Consultant
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationJennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii
Individualized Diabetes Treatment for the Elderly Jennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii Extremely Relevant Baby Boomers are aging! ¼ of people age
More informationManagement of adults with diabetes undergoing surgery and elective procedures: Improving standards
Management of adults with diabetes undergoing surgery and elective procedures: Improving standards Revised September 2015 Changes in the second edition of the peri-operative document Preoperative pathway
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationLong-Term Care Updates
Long-Term Care Updates January 2019 By Kristina Nikl, PharmD Several recent studies evaluating the management of diabetes in older adults have concluded that 25-52% of elderly patients are currently being
More informationMedicines Optimisation Team Standard Operating procedure for Alogliptin Audit:
Medicines Optimisation Team Standard Operating procedure for Alogliptin Audit: To review type 2 diabetic patients prescribed dipedtidylpeptidase-4 (DPP-4) inhibitors (linagliptin (Trajenta, saxagliptin
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationThe older person with co morbidities. Eugene Hughes General Practitioner Isle of Wight
The older person with co morbidities Eugene Hughes General Practitioner Isle of Wight Eugene Hughes Age 60 BMI 26.5 BP 125/70 Alcohol intake moderate (?) TC 5.6 Regular exercise Non smoker Stress free
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationNational Institute for Health and Care Excellence. Type 2 diabetes. Stakeholder Comments Draft Guideline
National Institute for Health and Care Excellence Type 2 diabetes Stakeholder Comments Draft Guideline NOTE: NICE is unable to accept comments from non-registered organisations or individuals. If you wish
More informationWhen and how to start insulin therapy in type 2 diabetes
When and how to start insulin therapy in type 2 diabetes Anne Kilvert MD, FRCP Most patients with type 2 diabetes will eventually require insulin due to the progressive decline in betacell function. Dr
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationPERIOPERATIVE DIABETES GUIDELINE
PERIOPERATIVE DIABETES GUIDELINE This Guideline does not replace the need for the application of clinical judgment in respect to each individual patient. Background Diabetes mellitus is estimated to affect
More informationDiagnosis and management of diabetes in older people
Diagnosis and management of diabetes in older people Anne Kilvert 1 MD, FRCP, Consultant Physician Charles Fox 1 BM, FRCP, Consultant Physician 1 Northampton General Hospital, Cliftonville, Northampton,
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationSIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION
SIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION DR ROSE ZHAO-WEI TING ( 丁昭慧醫生 ) MBBS (HK), MRCP (UK), FHKCP, FHKAM (MEDICINE) Specialist in Endocrinology, Diabetes and Metabolism
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More informationHot Topics in Diabetic Kidney Disease a primary care perspective
Hot Topics in Diabetic Kidney Disease a primary care perspective DR SARAH DAVIES GP PARTNER WITH SPECIAL INTEREST IN DIABETES, CARDIFF DUK CLINICAL CHAMPION NB MEDICAL HOT TOPICS PRESENTER AND DIABETES
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationDiabetes and steroids: Storm conditions
Article Diabetes and steroids: Storm conditions June James Citation: James J (2016) Diabetes and steroids: Storm conditions. Journal of Diabetes Nursing 20: 128 33 Article points 1. Steroids are often
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationThere have been important changes in diabetes care which may not be covered in undergraduate textbooks.
Diabetes Clinical update There have been important changes in diabetes care which may not be covered in undergraduate textbooks. Changes in the diagnosis of diabetes a) HbA1C Since 2011, World Health Organisation
More informationMonitoring in Type 2 Diabetes. Learning Outcomes. Type 2 Diabetes. Senga Hunter Community Diabetes Specialist Nurse
Monitoring in Type 2 Diabetes Senga Hunter Community Diabetes Specialist Nurse Learning Outcomes Understand why blood monitoring is necessary Understand the blood tests for monitoring diabetes Understand
More informationDementia and Diabetes
Dementia and Diabetes Dr Jill Rasmussen RCGP Clinical Representative Dementia, jill.rasmussen@psi-napse.com 1 Dementia and Diabetes - Overview The Facts Implications for the Well Pathway Mild Cognitive
More informationComments. Type 2 Diabetes
Stakeholder organisation(s) (or your name if you are commenting as an individual): Name of commentator (leave blank if you are commenting as an individual): Document Comment (full version, short version
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationVolume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)
Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) The purpose of this special edition of the PACE Bulletin is to summarize the
More informationTreating the elderly patients with type 2 diabetes mellitus
Treating the elderly patients with type 2 diabetes mellitus Niki Katsiki MSc, PhD, MD, FRSPH IASO/EASO Scope Member EASD Diabetes & Cardiovascular Disease Group Member Member of the Executive Board of
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationPlacename CCG. Policies for the Commissioning of Healthcare
Placename CCG Policies for the Commissioning of Healthcare Policy for the Provision of Continuous Glucose Monitoring and Flash Glucose Monitoring to patients with Diabetes Mellitus. This document is part
More informationSummary of the risk management plan (RMP) for Synjardy (empagliflozin / metformin)
EMA/217413/2015 Summary of the risk management plan (RMP) for Synjardy (empagliflozin / metformin) This is a summary of the risk management plan (RMP) for Synjardy, which details the measures to be taken
More informationDiabetic Management in the Frail Older Patient
Diabetic Management in the Frail Older Patient A S S O C P R O F. P A U L V A R G H E S E, D I R E C T O R O F G E R I A T R I C M E D I C I N E, P R I N C E S S A L E X A N D R A H O S P I T A L. Outline
More informationPLEASE CHECK FULL SPECIFIC PRODUCT CHARACTERISTICS FOR MORE DETAILED AND CURRENT INFORMATION:
Metformin Standard tablets Modified-release tablets Metformin 1g sachets Metformin liquid 500mg/5ml (avoid use as expensive) < 2.00 5.32 for 56 tabs 500mg 13.16 for 60 sachets > 120 Ketoacidosis General
More informationDiabetes mellitus. Treatment
Diabetes mellitus Treatment Recommended glycemic targets for the clinical management of diabetes(ada) Fasting glycemia: 80-110 mg/dl Postprandial : 100-145 mg/dl HbA1c: < 6,5 % Total cholesterol: < 200
More informationIntegrated Community Diabetes Services (ICDS) GP Referral Guide Version 3 - October 2014
Integrated Community Diabetes Services (ICDS) GP Referral Guide Version 3 - October 2014 Introduction The Integrated Community Diabetes Service (ICDS) will deliver high quality care to individuals who
More informationWHO Guidelines for Management of Diabetes in Low Resource Settings
WHO Guidelines for Management of Diabetes in Low Resource Settings 24 th November, 2018 Dr. Alok Shetty K Senior Resident Department of Medicine St. John s Medical College & Hospital WHO vs ADA-EASD Revisiting
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 5 PURPOSE To assure that DOP inmates with Diabetes are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers are to follow these guidelines when treating
More informationPre admission & surgery Pre-admission Nurses Association SIG Catherine Prochilo Credentialled Diabetes Nurse Educator Sat 23 March 2013
Pre admission & surgery Pre-admission Nurses Association SIG Catherine Prochilo Credentialled Diabetes Nurse Educator Sat 23 March 2013 www.diabetesvic.org.au Plan/ overview Issue/ presenting problems
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationDisclosures of Interest. Publications Diabetologia Key points to emphasize
Disclosures of Interest No conflicts or disclosures How to Use the American Diabetes Association s Type 2 Diabetes Treatment Algorithm Rashida Downing, MD, FAAFP Primary Care Physician JenCare Medical
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationCase study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease
Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease Authored by Paul Zimmet and Richard Nesto on behalf of the Global Partnership for Effective Diabetes Management.
More informationBarns Medical Practice Service Specification: Diabetes
Barns Medical Practice Service Specification: Diabetes DEVELOPED June 2017 REVIEW DATE June 2019 Introduction Diabetes mellitus is a life-long progressive condition that can be controlled but not cured.
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationElevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC
Elevation of Serum Creatinine: When to Screen, When to Refer Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Presented at the University of Calgary s CME and Professional Development 2006-2007
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationERBP Guideline on management of diabetics with advanced CKD
ERBP Guideline on management of diabetics with advanced CKD ERBP Mission improve the outcome of patients with kidney disease in a sustainable way, through enhancing the accessibility of knowledge on patient
More informationAcute Stroke - Management of Hyperglycaemia. Contents
Acute Stroke - Management of Hyperglycaemia Classification: Policy Lead Author: Dr Amir Ahmad Additional author(s): Dr Jouher Kallingal, Professor Bob Young, Professor Pippa Tyrrell Authors Division: :
More informationDPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes
THERAPY REVIEW DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes STEVE CHAPLIN SPL DPP-4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixeddose
More informationdulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd.
dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd. 04 December 2015 The Scottish Medicines Consortium (SMC) has completed its
More informationType 2 diabetes: recent advances in diagnosis and management
DRUG REVIEW n Type 2 diabetes: recent advances in diagnosis and management Sudesna Chatterjee MD, FRCP and Melanie Davies MD, FRCP, FRCGP The expanding array of new type 2 diabetes agents and how to combine
More informationFasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period
Fasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period Dr Ketan Dhatariya MBBS MSc MD MS FRCP Consultant in Diabetes and Endocrinology Norfolk and Norwich
More informationGUIDELINES FOR THE MANAGEMENT OF DIABETES IN PALLIATIVE CARE
GUIDELINES FOR THE MANAGEMENT OF DIABETES IN PALLIATIVE CARE 16.1 GENERAL PRINCIPLES Diabetes occurs more frequently in palliative care patients than the general population. 1 Patients with pancreatic
More informationType 2 diabetes in adults: controlling your blood glucose by taking a second medicine what are your options?
Patient decision aid Type 2 diabetes in adults: controlling your blood glucose by taking a second medicine what are your options? nice.org.uk/guidance/ng28 Published: December 2015 About this decision
More informationTitle Peri-operative Guidelines for the Management of Patients with Diabetes. Author s job title Diabetes Specialist Nurse Department.
Patients with Document Control Title Peri-operative Guidelines for the Management of Patients with Author Directorate Medicine Version Date Issued 0.1 Jan 2011 Status Draft Initial version Author s job
More informationCase study: Lean adult with no complications, newly diagnosed with type 2 diabetes
Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Authored by Clifford Bailey and James LaSalle on behalf of the Global Partnership for Effective Diabetes Management. The
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationSpecial thanks to the EJC Foundation for their support of Sanford Center Geriatric Specialty Clinic
Special thanks to the EJC Foundation for their support of Sanford Center Geriatric Specialty Clinic Sanford Center for Aging 775-784-4744 med.unr.edu/aging Diabetes Management Series: From Selfmanagement
More informationThe York Diabetes Care Model
This Session The York Diabetes Care Model The annual review what s it for and how to do it How to make the diagnosis of diabetes and who to test Categorisation of diabetes at diagnosis Basics of Insulin
More informationPolicy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus Version No. Changes Made Version of July 2018 V0.5 Changes made to the policy following patient engagement including: - the
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More informationDiabetes and the Elderly: Medication Considerations When Determining Benefits and Risks
Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks Gretchen M. Ray, PharmD, PhC, BCACP, CDE Associate Professor UNM College of Pharmacy September 7 th, 2018 DISCLOSURES
More informationPharmacological Glycaemic Control in Type 2 Diabetes
Pharmacological Glycaemic Control in Type 2 Diabetes Aim(s) and Objective(s) This guideline aims to offer advice on the pharmacological management for those who require measures beyond diet and exercise
More informationInsulin use in Type 2 Diabetes
Insulin use in Type 2 Diabetes 1 Conflict of Interest I have been on advisory boards or had speaker fees from the following pharmaceutical companies: - Eli Lilly - Novo Nordisk - Sanofi Aventis - MSD -
More informationDiabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh
Diabetes Mellitus Medical Management and Latest Developments Dr Ahmad Abou-Saleh What is Diabetes Mellitus? A disease characterised by a state of chronic elevation of blood glucose levels due to: - The
More informationGuidance on the Self-Monitoring of Blood Glucose in Adults with Diabetes
Introduction Guidance on the Self-Monitoring of Blood Glucose in Adults with Diabetes This guideline is designed to offer guidance for primary and secondary care on the use of selfmonitoring of blood glucose
More informationPlacename CCG. Policies for the Commissioning of Healthcare
Placename CCG Policies for the Commissioning of Healthcare Policy for the funding of insulin pumps and continuous glucose monitoring devices for patients with diabetes 1 Introduction 1.1 This document
More informationToward a Comprehensive Diabetes Care Model for Older People
Toward a Comprehensive Diabetes Care Model for Older People Professor L. Rodriguez Mañas Hospital Universitario de Getafe Madrid, Spain Professor Alan J Sinclair Professor of Medicine and Consultant Diabetologist
More informationOral Treatments. SaminaAli Prescribing Support Pharmacist
Oral Treatments for Type 2 Diabetes SaminaAli Prescribing Support Pharmacist Learning Outcomes National Guidance Familiar with classes of oral hypoglycaemic agents (OHAs) used in controlling blood glucose
More informationThis guideline was adapted in collaboration with Dr Georgina Walker and the Palliative Care Team at Rowcroft Hospice. With thanks.
Title: Directorate: Responsible for review: Ratified by: DIABETES, MANAGEMENT OF IN PALLIATIVE CARE PATIENTS General Medicine Diabetes Specialist Nurse Service Delivery Unit Clinical Director of Pharmacy
More informationMr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)
Dr David Kim Endocrinologist and General Physician Waitemata DHB and Apollo Specialist Clinic Albany Auckland Mr Rab Burtun Diabetes Nurse Specialist Waitemata DHB Waitakere Hospital Auckland 8:30-10:30
More information